Loftware Acquires PrisymID

We are excited to announce that Loftware has acquired PRISYM ID.

Join us to learn how bringing together two leaders in medical device and pharmaceutical labeling will help you unlock new opportunities by offering cloud-based solutions to address all your evolving requirements including clinical trials labeling.

You’ll hear firsthand from Loftware President and CEO, Robert O’Connor Jr. and PRISYM ID CEO, Richard Adams. They will discuss how this union unites the best talent in medical device and pharmaceutical labeling and further strengthens Loftware’s ability to meet labeling complexities and evolving regulatory demands for customers across ALL industries. You’ll also find out how customers will benefit from scale and investment, expanded global presence and increased service and support.

Register today to find out how our unmatched domain expertise will fuel development and innovation in the medical device, pharmaceutical and clinical trials space and beyond.


H2 - Heading

Ut volutpat massa a purus congue, a tincidunt nisl finibus. Nulla non turpis in elit iaculis porta. Maecenas turpis metus, pellentesque eget augue quis, venenatis dapibus felis. Donec non varius sapien, et blandit erat. Proin vel neque nibh. Ut facilisis, neque feugiat mattis ullamcorper, augue purus dictum nibh, at faucibus neque justo ut tortor. Sed tristique, ex eu laoreet aliquet, elit nisl lobortis nibh, ut pellentesque erat ex ut magna. Suspendisse sed feugiat nulla. Duis ac justo orci. Praesent luctus mauris sed malesuada dignissim. Cras sit amet ante quis magna elementum laoreet sit amet at mauris.

H3 - Heading

Sed tristique, ex eu laoreet aliquet, elit nisl lobortis nibh, ut pellentesque erat ex ut magna. Suspendisse sed feugiat nulla.

H3 - Heading

Sed tristique, ex eu laoreet aliquet, elit nisl lobortis nibh, ut pellentesque erat ex ut magna. Suspendisse sed feugiat nulla.

H3 - Heading

Sed tristique, ex eu laoreet aliquet, elit nisl lobortis nibh, ut pellentesque erat ex ut magna. Suspendisse sed feugiat nulla.